Article thumbnail

Targeting the cell cycle for cancer therapy

By A Carnero


Most if not all neoplasias show a directly or indirectly deregulated cell cycle. Targeting its regulatory molecules, the cyclin-dependent kinases, as a therapeutic mode to develop new anticancer drugs, is being currently explored in both academia and pharmaceutical companies. The development of new compounds is being focused on the many features of the cell cycle with promising preclinical data in most fields. Moreover, a few compounds have entered clinical trials with excellent results maintaining the high hopes. Thus, although too early to provide a cell cycle target based new commercial drug, there is no doubt that it will be an excellent source of new anticancer compounds

Topics: Review Article
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1995). Biol 287(5): 821–828 Pines J
  2. (1996). Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 380: 548–550
  3. (1994). Mammalian G1 cyclins. Curr Opin Cell Biol 6(6): 842–846 Eckstein JW (2000) Cdc25 as a potential target of anticancer agents. Invest New Drugs 18:(2):): 149–156 Fahraeus
  4. (1998). Myc and the cell cycle. Front Biosci 3: D250–D268
  5. (1997). p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 57: 1442–1446 Carnero A, Hannon GJ
  6. (1991). Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins.
  7. (1999). The p53 pathway.